These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 6435685)
1. Calcium-dependent aggregation of human serum amyloid P component. Inhibition by the cyclic 4,6-pyruvate acetal of galactose. Hind CR; Collins PM; Pepys MB Biochim Biophys Acta; 1984 Nov; 802(1):148-50. PubMed ID: 6435685 [TBL] [Abstract][Full Text] [Related]
2. Binding specificity of serum amyloid P component for the pyruvate acetal of galactose. Hind CR; Collins PM; Renn D; Cook RB; Caspi D; Baltz ML; Pepys MB J Exp Med; 1984 Apr; 159(4):1058-69. PubMed ID: 6707579 [TBL] [Abstract][Full Text] [Related]
3. Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteria. Hind CR; Collins PM; Baltz ML; Pepys MB Biochem J; 1985 Jan; 225(1):107-11. PubMed ID: 3883985 [TBL] [Abstract][Full Text] [Related]
4. Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits. Hind CR; Collins PM; Caspi D; Baltz ML; Pepys MB Lancet; 1984 Aug; 2(8399):376-8. PubMed ID: 6147456 [TBL] [Abstract][Full Text] [Related]
5. Calcium-dependent aggregation of human serum amyloid P component. Baltz ML; De Beer FC; Feinstein A; Pepys MB Biochim Biophys Acta; 1982 Feb; 701(2):229-36. PubMed ID: 7074110 [TBL] [Abstract][Full Text] [Related]
7. Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Hutchinson WL; Hohenester E; Pepys MB Mol Med; 2000 Jun; 6(6):482-93. PubMed ID: 10972085 [TBL] [Abstract][Full Text] [Related]
8. Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component. de Beer FC; Baltz ML; Holford S; Feinstein A; Pepys MB J Exp Med; 1981 Oct; 154(4):1134-9. PubMed ID: 6793685 [TBL] [Abstract][Full Text] [Related]
9. Calcium-enhanced aggregation of serum amyloid P component and its inhibition by the ligands heparin and heparan sulphate. An electron microscopic and immunoelectrophoretic study. Nielsen EH; Sørensen IJ; Vilsgaard K; Andersen O; Svehag SE APMIS; 1994 Jun; 102(6):420-6. PubMed ID: 8068301 [TBL] [Abstract][Full Text] [Related]
10. The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. Thompson D; Pepys MB; Tickle I; Wood S J Mol Biol; 2002 Jul; 320(5):1081-6. PubMed ID: 12126626 [TBL] [Abstract][Full Text] [Related]
11. A structure-activity study on the sucrose taste antagonist methyl 4,6-dichloro-4,6-dideoxy-alpha-D-galactopyranoside. Vlahopoulos V; Jakinovich W J Neurosci; 1986 Sep; 6(9):2604-10. PubMed ID: 3746425 [TBL] [Abstract][Full Text] [Related]
12. Structure of pentameric human serum amyloid P component. Emsley J; White HE; O'Hara BP; Oliva G; Srinivasan N; Tickle IJ; Blundell TL; Pepys MB; Wood SP Nature; 1994 Jan; 367(6461):338-45. PubMed ID: 8114934 [TBL] [Abstract][Full Text] [Related]
13. Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: enhanced binding at slightly acid pH. Danielsen B; Sørensen IJ; Nybo M; Nielsen EH; Kaplan B; Svehag SE Biochim Biophys Acta; 1997 Apr; 1339(1):73-8. PubMed ID: 9165101 [TBL] [Abstract][Full Text] [Related]
14. Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. Ashton AW; Boehm MK; Gallimore JR; Pepys MB; Perkins SJ J Mol Biol; 1997 Sep; 272(3):408-22. PubMed ID: 9325100 [TBL] [Abstract][Full Text] [Related]
15. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Pepys MB; Dyck RF; de Beer FC; Skinner M; Cohen AS Clin Exp Immunol; 1979 Nov; 38(2):284-93. PubMed ID: 118839 [TBL] [Abstract][Full Text] [Related]
16. The structure and binding characteristics of serum amyloid protein (9.5S alpha 1-glycoprotein). Painter RH; De Escallón I; Massey A; Pinteric L; Stern SB Ann N Y Acad Sci; 1982; 389():199-215. PubMed ID: 6807178 [TBL] [Abstract][Full Text] [Related]
17. Binding characteristics of human serum amyloid P component. Serban D; Rordorf-Adam C Scand J Immunol; 1987 Mar; 25(3):275-81. PubMed ID: 3105045 [TBL] [Abstract][Full Text] [Related]
18. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Pepys MB; Rademacher TW; Amatayakul-Chantler S; Williams P; Noble GE; Hutchinson WL; Hawkins PN; Nelson SR; Gallimore JR; Herbert J Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5602-6. PubMed ID: 8202534 [TBL] [Abstract][Full Text] [Related]
19. Amyloid 'degrading factor activity': a non-specific calcium-mediated effect. Scott DL; Bracken P; Bacon PA; Husby G Clin Sci (Lond); 1985 Mar; 68(3):333-9. PubMed ID: 3918827 [TBL] [Abstract][Full Text] [Related]
20. Suppression of T cell cytotoxicity by nude mouse spleen cells: reversal by monosaccharides and interleukin 2. Palladino MA; Ranges GE; Scheid MP; Oettgen HF J Immunol; 1983 May; 130(5):2200-2. PubMed ID: 6220084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]